The treatment of benign prostatic hyperplasia with α1-adrenoceptor antagonists;Die Behandlung der BPH mit α1-Adrenozeptorantagonisten

Urologe - Ausgabe A

Volumn 36, Issue 1, 1997, Pages 18-34

  Heimbach, D ^a   Muller S C ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

adrenoceptor antagonists; alfuzosin; BPH; doxazosin; tamsulosin; terazosin

Indexed keywords

ALFUZOSIN; ALNA; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DIBLOCIN; DOXAZOSIN; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; HUMAN; MALE; PROSTATE HYPERTROPHY; REVIEW;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DOUBLE-BLIND METHOD; HUMANS; MALE; PROSTATE; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ADRENERGIC, ALPHA-1; TREATMENT OUTCOME;

EID: 0031055991     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001200050062     Document Type: Review

References (157)

1. Abrams P, Hollister P, Lawrence J, Doyle PT, Sherwood T, Whitaker RH (1982) Bladder outflow obstruction treated with Phenozxybenzamine. Preliminary note. Br J Urol 54: 530
2. Abrams P, Shah PJR, Stone R. Choa RG (1982) Bladder outflow obstruction treated with Phenoxybenzamine. Br J Urol 54: 527-530
3. Abrams P, Schulman CC, Vaage S (1995) Tamsulosin, a selective α1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 76: 325-336
4. Ahsan Z, English P, Bailey M, Abel P, Ramsay J, Redhead R (1994) Efficacy of Indoramin in the long term treatment of benign prostatic hyperplasia. Proceedings of the 23rd Congress of the SIU, Sydney, 100, Abs 97
5. Arnold RJG, Kaniecki DJ, McNutt R, Rouhani R, Pettit K, Lowe FC (1996) Creation of a Markov model to predict the costs of various treatments of benign prostatic hyperplasia (BPH) from patient, physician, and health administrator perspectives. J Urol 155 [Suppl]: 452 a, Abs 567
6. Ball AJ, Feneley RCC, Abrams PH (1981) The natural history of untreated "prostatism". Br J Urol 53: 613-616
7. Barry MJ, Cockett ATK, Holtgrewe HL, McConnel JD, Sihelnik HN, Winfield HN (1993) Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of severity of benign prostatic hyperplasia. J Urol 150: 351-358
8. Bartsch G, Müller HJ, Oberholzer M, Rohr HP (1979) Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 122: 487-491
9. Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132: 474-479
10. Boreham PF, Braithwaite P, Milewski P, Pearson H (1977) Alpha-adrenergic blockers in prostatism. Br J Surg 64: 756-759
11. Boyle P (1994) Epidemiology of benign prostatic hyperplasia: Risk factors and concomitance with hypertension. Br J Clin Pract 74 [Suppl]: 18-22
12. Brawer MK, Adams G, Epstein H (1993) Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. Arch Fam Med 2: 929-935
13. Brooks ME, Sidi AA, Hanani Y, Braf ZV (1983) Ineffectiveness of Phenoxybenzamine in treatment of benign prostatic hypertrophy. Urology 21: 474-478
14. Buzelin JM, Hebert M, Blondin P (1993) Alpha-blocking treatment with Alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with Prazosin. The PRAZALF Group. Br J Urol 72: 922-927
15. Buzelin JM, Geffriaud-Ricouard C, Delauche-Cavallier MC, Weber F, Proffit O, Roth S (1995) A double-blind, placebo-controlled trial of the efficacy and safty of sustained-release Alfuzosin in symptomatic benign prostatic hyperplasia. J Urol 153 [Suppl]: 274a, Abs 184
16. Caine M, Raz S, Ziegler M (1975) Adrenergic and cholinergic receptors in the human prostatic capsule and bladder neck. Br J Urol 47: 193-202
17. Caine M, Pfau A, Perlberg S (1976) The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 138: 979-983
18. Caine M, Perlberg S, Meretyk S (1978) A placebo-controlled double-blind study of the effect of Phenozxybenzamine in benign prostatic obstruction. Br J Urol 50: 551-554
19. Caine M, Perlberg S, Shapiro A (1981) Phenoxybenzamine for benign prostatic obstruction. Urology 17: 542-546
20. Caine M (1986) The present role of alpha adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 136: 1-4
21. Carbin BE, Bauer P, Friskand M, Moyse D (1991) Efficacy of Alfuzosin (an α1-adrenoreceptor blocking drug) in benign hyperplasia of the prostate. Scand J Urol Nephrol 138 [Suppl]: 73-75
22. Chapple CR, Christmas TJ, Milroy EJG (1990) A twelve week placebocontrolled study of Prazosin in the treatment of prostatic obstruction. Urol Int 45 [Suppl 1]: 47-55
23. Chapple CR, Stolt M, Abrams PH, Christmas TJ, Milroy EJ (1992) A 12-week placebo-controlled double blind study of Prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. Br J Urol 70: 285-294
24. Chappie CR, Noble JG, Milroy EJ (1993) Comparative study of selective αl-adrenoceptor blockade versus surgery in the treatment of prostatic obstruction. Br J Urol 72: 822-825
25. Chapple CR, Burt RP, Andersson PO, Greengrass P, Wyllie M, Marshall I (1994) Alpha 1-adrenoceptor subtypes in the human prostate. Br J Urol 74: 585-589
26. Chapple CR, Carter P, Christmas TJ, Kirby RS, Bryan J, Milroy EJ, Abrams P (1994) A three month double-blind study of Doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 74: 50-56
27. Chapple CR (1996) Tamsulosin: Tolerability in older and younger symptomatic BPH patients. J Urol 155 [Suppl]: 575a, Abs 1057
28. Chapple CR (1996) Selective α1-adrenoceptor antagonists in benign prostatic hyperplasia: Rationale and clinical experience. Eur Urol 29: 129-144
29. Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AFGVM, Abrams P (1996) Tamsulosin, the first prostate-selective al α1a-adrenoceptor antagonist. Eur Urol 29: 155-167
30. Chow W, Hahn D, Sandhu D, Slaney P, Henshaw R, Das G, Wells P (1990) Multicentre controlled trial of Indoramin in the symptomatic relief of benign prostatic hypertrophy. Br J Urol 65: 36-38
31. Christensen MM, Holme JB, Husted SE, Jacobsen F, Norgaard JP, Wolf H, Rasmussen PC, Nielsen J, Noer I, Olesen S (1990) Doxazosin, an α1-adrenoceptor-blocking agent in long term treatment of benign prostate obstruction. Eur Urol 18 [Suppl 1]: 299, Abs 576
32. Christensen MM, Bendix-Holme J, Rasmussen PC, Jacobsen F, Nielsen J, Norgaard JP, Olesen S, Noer I, Wolf H, Husted SE (1993) Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scand J Urol Nephrol 27: 39-44
33. Contreras BA, Kim JH, Rukstalis DB, Stcinberg GS, Gerber GS (1996) Urodynamic evaluation of men with benign prostatic hyperplasia (BPH) treated with Doxazosin. J Urol 155 [Suppl]: 573 a, Abs 1050
34. Costa P, Geffriaud C, Delauche M-C, Velut V, Proffit O, Bennaoum K, Bressolle F (1994) Effect of a single dose of Alfuzosin SR on flow rate in elderly patients with symptomatic benign prostatic hyperplasia (BPH). Proc of the 11th Congress of the EAU, Berlin, p 23, Abs 45
35. Debruyne FMJ, Lodewijk D, Arocena F, Kirk D (1995) Efficacy of Terazosin in benign prostatic hyperplasia from a randomized withdrawal International Terazosin Trial (ITT). J Urol 153 [Suppl]: 273a, Abs 177
36. De la Rosette JJ, Karthaus HF, van Kerrebroeck PE, de Boo T, Debruyne FM (1992) Research in 'prostatitis syndromes': the use of Alfuzosin (a new α1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities. Eur Urol 22: 222-227
37. Delmas V, Coulange C, Caillć P, Geffriaud C, Proffit O, Delauche-Cavallier MC and the Dalbi Group (1994) A placebo controlled double blind study of sustained release Alfuzosin in benign prostatic hyperplasia. Proc of the 11th Congress of the EAU, Berlin, p 24, Abs 47
38. Di Silverio F (1992) Use of Terazosin in the medical treatment of benign prostatic hyperplasia. Experience in Italy. Br J Urol 70 [Suppl 1]: 22-26
39. Dunzendorfer U (1988) Clinical experience: Symptomatic management of BPH with Terazosin. Urology 32 [Suppl]: 27-31
40. Dutkiewicz S, Witeska A (1995) Doxazosin-An α1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (part one). Int Urol Nephrol 27: 311-318
41. Dutkiewicz S, Witeska A, Stcepien K (1995) Doxazosin-An α1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (BPH) (part two). Int Urol Nephrol 27: 413-417
42. Elhilali MM, Ramsey EW, Barkin J et al. (1996) A multicenter, double-blind, placebo-controlled study to evaluate the safety and efficacy of Terazosin in the treatment of benign prostate hyperplasia. Urology 47: 335-342
43. Eri LM, Tveter KJ (1995) Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 154: 923-934
44. Fabricius PG, Weizert P, Dunzendorfer U, Mac Hannaford JM, Maurath C (1990) Efficacy of once-a-day Terazosin in benign prostatic hyperplasia: A randomized, double-blind, placebo-controlled clinical trial. Prostate 3 [Suppl]: 85-93
45. Fabricius PG, Mac Hannaford JM (1992) Placebo-controlled study of Terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up. Br J Urol 70 [Suppl 1]: 10-16
46. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N (1995) Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 154: 129-130
47. Fawzy A, Sullivan J, Cook E, Wallin D, Gonzalez F (1996) Long-term (4-year) efficacy of Doxazosin for the treatment of benign prostatic hyperplasia. J Urol 155 [Suppl]: 573 a, Abs 1051
48. Ferrie BG, Paterson PJ (1987) Phenoxybenzamine in prostatic hypertrophy. Br J Urol 59: 63-65
49. Folgar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G (1995) Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 288: 201-207
50. Ford APDW, Williams TJ, Blue DR, Clarke DE (1994) Alpha 1-adrenoceptor classification: sharpening Occam's razor. Trends Pharmacol Sci 15: 167-170
51. Forrey C, Bard JA, Wetzel JM et al. (1994) The α1-adrenoceptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned α1c-subtype. Mol Pharmacol 45: 703-708
52. Fowler FJ, Wennberg JE, Timothy RP, Barry MJ, Mulley AG, Hanley D (1988) Symptom status and quolity of life following prostatectomy. JAMA 259: 3018-3022
53. Fulton B, Wagstaff AJ, Sorkin EM (1995) Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 49: 295-320
54. Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T, Izumi T, Akibo Y (1982) Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 128: 836-841
55. Gerstenberg T, Blaabjerg J, Nielsen ML, Clausen S (1980) Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia. Invest Urol 18: 29-31
56. Giberti C, Damonte P, Michelotti P, Martorana G (1984) The effect of Thyroxamine in benign prostatic hypertrophy: a double-blind cross-over study. IRCS Med Sci 12: 591-596
57. Gillenwater JY, Mobley DL (1993) A sixteen week, double-blind, placeo-controlled, dose-titration study using Doxazosin tablets for the treatment of benign prostatic hyperplasia (BPH) in normotensive males. A multicenter study group. J Urol 149: 324a, Abs 447
58. Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, Dias N (1995) Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 154: 110-115
59. Girman CJ, Panser LA, Chute CG, Oesterling JE, Barrett DM, Chen CC, Arrighi HM, Guess HA, Lieber MM (1993) Natural history of prostatism: Urinary flow rates in a community-based study. J Urol 150: 887-892
60. Gleasson DM, Bottacini MR (1994) Effect of Terazosin on urine storage and voiding in the aging male with prostatism. Neurourol Urodyn 13: 1-12
61. Goetz AS, Lutz MW, Rimele TJ, Saussy DLJ (1994) Characterization of α1 adrenoceptor subtypes in human and canine prostate membranes. J Pharmacol Exp Ther 271: 1228-1233
62. Gormley GJ, Stoner E, Bruskewitz RC et al. (1992) The effect of Finasteride in men with benign prostatic hyperplasia. N Engl J Med 327: 1185-1191
63. Grasso M, Montesano A, Buonaguidi A et al. (1995) Comparative effects of Alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp de Urol 48: 97-103
64. Guthrie R (1994) Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: A primary care trial. J Fam Pract 39: 129-133
65. Hansen BJ, Nordling J, Mensink HG, Walter S, Meyhoff HH (1994) Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group. Scand J Urol Nephrol 157 [Suppl]: 169-176
66. Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, Takeda M (1994) Pharmacological evidence of distinct α1-adrenoceptor subtypes mediating the concentration of human prostatic urethra and peripheral artery. Br J Pharmacol 45: 703-708
67. Hayashida S, Hirasawa T, Uchiyama K, Shinohara Y, Mitui H, Nasu T (1994) The influence of Tamsulosin-Hydrochloride on benign prostatic hyperplasia - A comparison with Prazosine-Hydrochloride. Proc of the 23rd Congress of the SIU, Sydney, p 98, Abs 93
68. Hedlund H, Andersson KE, Ek A (1983) Effects of Prazosin in patients with benign prostatic obstruction. J Urol 130: 275-278
69. Hedlund H, Andersson KE (1988) Effects of Prazosin and Carbachol in patients with benign prostatic obstruction. Scand J Urol Nephrol 22:19-22
70. Heimbach D, Frohmüller H (1992) Anwendung von alpha-Rezeptorenblockern bei urologischen Erkrankungen. Dtsch Med Wochenschr 117: 825-828
71. Hieble JP, Boyce AJ, Caine M (1986) Comparison of the α-adrenoceptor characteristics in human and canine prostate. Fed Proc 45: 2609-2614
72. Hieble JP, Bylund DB, Clarke DE et al. (1995) International Union of Pharmacology. X. Recommendation for nomenclature of α1-adrenoceptors: Consensus update. Pharmacol Rev 47: 267-270
73. Holme BJ, Christensen MM, Rasmussen PC et al. (1994) 29-week Doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind, placebo-controlled study. Scand J Urol Nephrol 28: 77-82
74. Iacovou JW, Dunn M (1987) Indoramin. An effective new drug in the management of bladder outflow obstruction. Br J Urol 60: 526-528
75. The Italian Alfuzosin Cooperative Group (1995) Multicenter observational trial on sympthomatic treatment of benign prostatic hyperplasia with Alfuzosin: Clinical evaluation of impact on patient's quality of life. Eur Urol 27: 128-134
76. Irwin MB, Kim YH (1996) Acute urinary retention treated with Terazosin. J Urol 155 [Suppl] 572 a, Abs 1045
77. Izumi H, Kudo S, Fuino A, Yokoyama E, Ishibashi A (1989) The effect of Moxislyte-Hydrochloride in the symptomatic treatment of benign prostatic hyperplasia. Acta Urol Jap 35: 541-545
78. Jacobsen SJ, Oesterling JE, Lieber MM (1995) Community-based population studies on the natural history of prostatism. Curr Opin Urol 5: 13-17
79. Janknegt RA, Chapple CR (1993) Efficacy and safety of the α1-blocker Doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups. Eur Urol 24: 319-326
80. Jardin A, Bensadoun H, Belauche-Cavallier MC, Attali P (1991) Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet 337: 1457-1461
81. Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bourdillon A, Attali P (1994) Long-term treatment of benign prostatic hyperplasia with Alfuzosin: a 24-30 month survey. BPHALF Group. Br J Urol 74: 579-584
82. Jardin A, Kirby R, Christensen M, Jangknegt RA, Gillenwater J, Fawzy A (1995) Doxazosin is equally well-tolerated by older and younger normotensive men. J Urol 153 [Suppl]: 273 a, Abs 179
83. Kaplan SA, Soldo KA, Olsson CA (1994) Effect of dosing regimen on efficacy and safety of Doxazosin in normotensive men with symptomatic prostatism: a pilot study. Urology 44: 348-352
84. Kaplan SA, D'Alisera PM, Quiniones S, Soldo KA (1995) Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia: A study of safty and efficacy. Urology 46: 512-517
85. Kaplan SA, Soldo KA, Olsson CA (1995) Terazosin and Doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety. Eur Urol 28: 223-228
86. Kaplan SA (1996) Doxazosin in the older male: Efficacy in treating benign prostatic hyperplasia. Eur Urol 29 [Suppl]: 17-23
87. Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H and YM617 Clinical Study Group (1990) Use of an α1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol 144: 908-912
88. Kawabe K, Tsuchida S, Shimazaki J, Morita T, Yasuda K, Kageyama S (1993) Effect on Urapidil on benign prostatic hypertrophy: a multicenter, double-blind study. Urol Int 50: 27-32
89. Kawabe K (1995) Efficacy and safety of Tamsulosin in the treatment of benign prostatic hyperplasia. Br J Urol 76 [Suppl 1]: 63-67
90. Kirby RS, Coppinger SWC, Corcoran MO, Chapple CR, Flannigan M, Milroy EJG (1987) Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Br J Urol 60: 136-142
91. Kirby RS (1995) Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology 46: 182-186
92. Kumamoto Y, Tsukamoto T, Yachiku S et al. (1990) A double-blind trial on the effect of Bunazosin-Hydrochloride for the symptoms of benign prostatic hypertrophy. Acta Urol Jap 36: 1213-1218
93. Langer SZ (1974) Presynaptic regulation of catecholamine release. Br J Pharmacol 60: 481-497
94. LeDuc A, Cariou G, Baron C et al. (1990) A multicenter, double-blind, placebo-controlled trial of the efficacy of Prazosin in the treatment of dysuria associated with benign prostatic hypertrophy. Urol Int 45 [Suppl 1]: 56-62
95. Lepor H, Gup DI, Baumann M, Shapiro F (1988) Laboratory assessment of Terazosin and α1-blockade in prostatic hyperplasia. Urology 32 [Suppl 6]: 21-26
96. Lepor H, Henry H, Laddu AR (1991) The efficacy and safety of Terazosin for the treatment of symptomatic BPH. Prostate 18: 345-355
97. Lepor H, Auerbach S, Puras-Baez A et al. (1992) A randomized, placebo-controlled multicenter study of the efficacy and safety of Terazosin in the treatment of benign prostatic hyperplasia. J Urol 148: 1467-1474
98. Lepor H, Laddu A (1992) Terazosin in the treatment of benign prostatic hyperplasia: the United States experience. Br J Urol 70 [Suppl 1]: 2-9
99. Lepor H, Machi G (1992) The relative efficacy of Terazosin versus Terazosin and Flutamide for the treatment of symptomatic BPH. Prostate 20: 89-95
100. Lepor H, Meretyk S, Knapp-Malaoney G (1992) The safety, efficacy and compliance of Terazosin therapy for benign prostatic hyperplasia. J Urol 147: 1554-1557
101. Lepor H, Soloway M, Appell R, Clifton G, Manski R, Laddu A (1992) A double-blind randomized, multicenter trial involving comparison of Terazosin and placebo in patients with benign prostatic hyperplasia. Proc of the 10th Congress of the EAU, Genoa, p 309, Abs 215
102. Lepor H, Tang R, Meretyk S, Shapiro E (1993) Alpha 1-adrenoceptor subtypes in the human prostate. J Urol 149: 640-642
103. Lepor H (1995) Long-term efficacy and safety of Terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 45: 406-413
104. Lepor H (1995) Combination medical therapy for benign prostatic hyperplasia. Urol Clin North Am 22: 401-405
105. Lepor H, Multicenter Study Group (1995) Long-term efficacy and safety of Doxazosin for the treatment of benign prostatic hyperplasia. J Urol 153 [Suppl]: 273a, Abs 180
106. Lepor H, Tamsulosin Investigator Group (1995) Clinical Evaluation of Tamsulosin, a prostate selective α1c-antagonist. J Urol 153 [Suppl]: 274 A
107. Lepor H (1996) Does prostate volume (PV) predict response to Terazosin and Finasteride monotherapy and Terazosin/Finasteride combination therapy? A subset analysis of the VA Cooperative BPH Medical Therapy Study. J Urol 155 [Suppl]: 574a, Abs 1052
108. Lloyd SN, Buckley JF, Chilton CP, Ibrahim I, Kaisary AV, Kirk D (1992) Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial. Br J Urol 70 [Suppl 1]: 17-21
109. Lloyd SN, McMahon A, Muller W, Buckley JF, Deane RF, Kirk D, Ksyle KF (1992) Is Indoramin an effective alternative to prostatectomy? Br J Urol 70: 408-411
110. Lowe FC (1994) Safety assessment of Terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 44: 46-51
111. Lowe FC, McDaniel RL, Chmiel JJ, Hillman AL (1995) Economic modeling to assess the costs of treatment with Finasteride, Terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology 46: 477-483
112. Lukacs B, McCarthy C, Grange JC (1993) Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an α1-adrenergic blocker, Alfuzosin. Qal BPH Study Group in General Practice. Eur Urol 24 [Suppl 1]: 34-40
113. Lukacs B, Blondin P, McCarthy C, Du Boys B, Grippon P, Lasalle C (1996) Safety profile of 3 months' therapy with Alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur Urol 29: 29-35
114. Lukacs B, Comet D, Doublet D, Gattegno B, Thibault P (1996) Two-year assessment of long-term health related quality of life (HRQL) of 4,951 patients suffering from benign prostatic hypertrophy (BPH) treated with a uroselective α1-blocker, Alfuzosin. J Urol 155 [Suppl]: 574a, Abs 1053
115. Martelli A, Pacifico P, Casadai G (1993) Effect of Alfuzosin on quality of life in benign prostatic hyperplasia patients: preliminary results. Italian Alfuzosin Co-Operative Group. Eur Urol 24 [Suppl 1]: 28-33
116. Martorana G, Giberti G, Damonte P, Ciprandi G, Dirienzo W, Giuliana L (1984) The effect of Prazosin in benign prostatic hypertrophy, a placebo controlled double-blind study. IRCS Med Sci 12: 11-16
117. Martorana G, Giberti C, Pacella M, Casadei G, Pacifico P, Giuliana L (1994) Urodynamic effects of Alfuzosin on outlet obstruction of benign prostatic hyperplasia patients. Proc of the 11th Congress of the EAU, Berlin, p 22, Abs 42
118. Matzkin H, Soloway MS, Rangel MC, Laddu A (1992) Efficacy of Terazosin in patients with benign prostatic hyperplasia. Eur Urol 21: 126-130
119. McConnel JD (1995) Benign prostatic hyperplasia: Treatment guidelines and patient classification. Br J Urol 76 [Suppl 1]: 29-46
120. McGrath JC, Brown CM, Wilson VG (1989) Alpha-adrenoceptors: a critical review. Med Res Rev 9: 407-533
121. Melchior H (1995) Kostenentwicklung im deutschen Gesundheitswesen. Dtsch Ges Urol 11: 206-208
122. Michel MC, Büscher R, Kerker J, Kraneis H, Erdbrügger W, Brodde O-E (1993) Alpha-1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Evidence for heterogenity of chloroethylclonidine-resistant rat renal α1-adrenoceptors. Naunyn-Schmiedebergs Arch Pharmacol 348: 385-395
123. Michel MC, Grübbel B, Möllhoff S, Otto T, Gerhardts W, Kröpfl D (1994) Alpha-1-adrenoceptor affinities of drugs for the treatment of benign prostatic hyperplasia in human prostate, rat tissues and at cloned subtypes. Proc 23rd Congress SIU, Sydney, p 254, Abs 649
124. 3H-Tamsulosin to α1-adrenergic receptor (AR) subtypes. Proc 23rd Congress SIU, Sydney, p 262, Abs 680
125. Mobley DF (1996) Doxazosin in patients with benign prostatic hyperplasia: Effects as a function of baseline disease severity. J Urol 155 [Suppl]: 571 a, Abs 1043
126. Muramatsu I, Oshita M, Ohmura T, Kigoshi S, Akino H, Gobara M, Okada K (1994) Pharmacological characterization of α1-adrenoceptor subtypes in the human prostate: functional and binding studies. Br J Urol 74: 572-578
127. Nagy F, Hamvas A, Tanko A, Frang D (1990) Medical treatment of prostatic bladder outflow obstruction with Prazosin. Eur Urol 18 [Suppl 1]: 299, Abs 575
128. Naslund MJ, Stitcher MF (1996) Cost comparison of medical management and surgical prostatectomy for BPH. J Urol 155 [Suppl]: 268 a, Abs 161
129. Neumann HG (1993) Kombinationsbehandlung der benignen Proslatahyperplasie (BPH) mit Phytotherapie und selektiver α1-Blockade. Urologe B 33: 384-385
130. Park JC, Miyatake R, Kiwamoto H, Sugiyama T, Akiyama T, Kurila T (1994) Pressure-flow measurements in patients with benign prostatic hyperplasia before and after application of Tamsulosin-Hydrochloride. Proc of the 23rd Congress of the SIU, Sydney, p 98, Abs 94
131. Pool JL (1996) Unique aspects of Doxazosin: A third-generation α-blocker. Eur Urol 29 [Suppl]: 31-39
132. Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ (1993) Identification, quantification and localization of mRNA for three α1-adrenergic receptor subtypes in human prostate. J Urol 150: 546-551
133. Ramsay JWA, Scott GI, Whitfield HN (1985) A double-blind controlled trial of a new α1-blocking drug in the treatment of bladder outflow obstruction. Br J Urol 57: 657-659
134. Raz S, Zeigler M, Caine M (1973) Pharmacological receptors in the prostate. Br J Urol 45: 663-667
135. Roehrborn CG (1995) The newly established guidelines for the diagnosis and management of benign prostatic hyperplasia. Curr Opin Urol 5: 445-453
136. Roehrborn CG, Oesterling JE, Arbor A et al. (1996) Differences in outcomes between african americans (AA) and non-african americans following treatment with Terazosin and placebo for benign prostatic hyperplasia (BPH) in the Hytrin Community Assessment Trial (HYCAT). J Urol 155 [Suppl]: 571 a, Abs 1041
137. Roehrborn CG, Oesterling JE, Auerbach S, Kaplan A, Lloyd K, Milam DF, Padley RJ (1996) The Hytrin Community Assessment Trial Study: A oneyear study of Terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 47: 159-168
138. Ronchi F, Margonato A, Ceccardi R, Rigatti P, Rossini BM (1982) Symptomatic treatment of benign prostatic obstruction with Nicergoline: A placebo controlled study and urodynamic evaluation. Urol Res 10: 131-134
139. Roolema HJ, Rosier P, Janknegt RA, van Mastrigt R (1991) Efficacy of α-blocker (Doxazosin) in BPH appraised by pressure-flow (CLIM) analysis. Neurourol Urodynam 10: 295-299
140. Ruutu ML, Hansson E, Juusela HE et al. (1991) Efficacy and side-effects of Prazosin as a symptomatic treatment of benign prostatic obstruction. Scand J Urol Nephrol 25: 15-19
141. Schulman CC, Cortvriend J, Jonas U, Lock TMTW, Vaage S, Speakman MJ (1996) Tamsulosin, the first prostate-selective α1a-adrenoceptor antagonist. Eur Urol 29: 145-154
142. Schwinn D, Wilson K, Page S, Campell S, Kwatra M (1994) Tamsulosin is selective for cloned α1C-AR and α1A/D-subtypes. Proc 23rd Congress SIU, Sydney, 261, Abs 678
143. 3H)-rauwolscine. J Urol 135: 1038-1042
144. Starkey LP, Yasukawa K, Trenga C, Miyazawa Y, Ito Y (1994) Study of possible pharmacodynamic interaction between Tamsulosin and Nifedipine in subjects with essential hypertension. J Clin Pharmacol 34:1019, Abs 45
145. Stephenson TP, Jensen RD and the PRANALF Group (1994) A placebo-controlled study of the efficacy and tolerability of Alfuzosin and Prazosin for the treatment of benign prostatic hypertrophy (BPH). Proc of the 11th Congress of the EAU, Berlin, p 25, Abs 48
146. Stott MA, Abrams P (1991) Indoramin in the treatment of prostatic bladder outflow obstruction. Br J Urol 67: 499-501
147. Teillac P, Delauche-Cavallier MC, Attali P (1992) Urinay flow rates in patients with benign prostatic hypertrophy following treatment with Alfuzosin. DUALF Group. Br J Urol 70: 58-64
148. Testa R, Guarneri L, Ibba M et al. (1993) Characterization of α1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man. Eur J Pharmacol 249: 307-315
149. Tsunoo M, Shishito A, Soeshi Y, Kobori M, Shimoyama M (1990) Phase 1 clinical trial of YM 617, a new α1-adrenoccptor antagonist - First report: A single oral dose of conventional formulation in healthy male subjects. Rinsho Iyaku 6: 2503-2528
150. Tsunoo M, Shishito A, Soeshi Y, Kobori M, Shimoyama M (1990) Phase 1 clinical trial of YM 617, a new α1-adrenoceptor antagonist - Second report: A single oral dose of controlled release formulation in healthy male subjects. Rinsho Iyaku 6: 2529-2551
151. Tsunoo M, Shishito A, Soeshi Y, Kobori M, Shimoyama M (1991) Phase 1 clinical trial of YM 617, a new α1-adrenoceptor antagonist - Third report: Multiple oral doses of controlled release formulation in healthy male subjects. Rinsho Iyaku 7: 63-93
152. Wilde MI, Fitton A, McTavish D (1993) Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in benign prostatic hyperplasia. Drugs 45: 410-429
153. Witjes WPJ, Rosier PFWM, De Wildt MJAM, Van Iersel MP, Debruyne FMJ, De La Rosette JJMCH (1996) Urodynamic and clinical effects of Terazosin therapy in patients with symptomatic benign prostatic hyperplasia. J Urol 155: 1317-1323
154. Woods AT, (1992) The management of symptomatic benign prostatic hyperplasia with the once-a-day αa1-blocker Terazosin. Mil Med 157: 361-364
155. Yamada S, Suzuki M, Tanaka C et al. (1994) Comparative study on α1-adrenoceptor antagonist binding in human prostate and aorta. Clin Exp Pharmacol Physiol 21: 405-411
156. Yasuda K, Yamanishi T, Tojo M, Nagashima K, Akimoto S, Shimazaki J (1994) Effect of Naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies. Prostate 25: 46-52
157. Young RA, Brogden RN (1988) Doxazosin: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in mild to moderate hypertension. Drugs 355: 535-541